Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

bioAffinity Technologies (BIAF) Cash from Investing Activities (2023 - 2025)

Historic Cash from Investing Activities for bioAffinity Technologies (BIAF) over the last 3 years, with Q3 2025 value amounting to $3646.0.

  • bioAffinity Technologies' Cash from Investing Activities rose 13874.6% to $3646.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$60568.0, marking a year-over-year increase of 772.7%. This contributed to the annual value of -$79083.0 for FY2024, which is 9642.06% up from last year.
  • Latest data reveals that bioAffinity Technologies reported Cash from Investing Activities of $3646.0 as of Q3 2025, which was up 13874.6% from -$13427.0 recorded in Q2 2025.
  • bioAffinity Technologies' Cash from Investing Activities' 5-year high stood at $13442.0 during Q4 2023, with a 5-year trough of -$2.2 million in Q3 2023.
  • Its 3-year average for Cash from Investing Activities is -$213549.9, with a median of -$13427.0 in 2025.
  • Per our database at Business Quant, bioAffinity Technologies' Cash from Investing Activities plummeted by 63258.22% in 2024 and then soared by 13874.6% in 2025.
  • Over the past 3 years, bioAffinity Technologies' Cash from Investing Activities (Quarter) stood at $13442.0 in 2023, then tumbled by 100.01% to -$1.0 in 2024, then surged by 364700.0% to $3646.0 in 2025.
  • Its Cash from Investing Activities was $3646.0 in Q3 2025, compared to -$13427.0 in Q2 2025 and -$50786.0 in Q1 2025.